242 related articles for article (PubMed ID: 26177647)
1. Immunotherapy of Melanoma.
Tarhini AA
Curr Mol Pharmacol; 2016; 9(3):196-207. PubMed ID: 26177647
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade and interferon-α in melanoma.
Rafique I; Kirkwood JM; Tarhini AA
Semin Oncol; 2015 Jun; 42(3):436-47. PubMed ID: 25965362
[TBL] [Abstract][Full Text] [Related]
3. The use of immunotherapy in the treatment of melanoma.
Achkar T; Tarhini AA
J Hematol Oncol; 2017 Apr; 10(1):88. PubMed ID: 28434398
[TBL] [Abstract][Full Text] [Related]
4. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of melanoma: a critical review of current concepts and future strategies.
Riker AI; Radfar S; Liu S; Wang Y; Khong HT
Expert Opin Biol Ther; 2007 Mar; 7(3):345-58. PubMed ID: 17309326
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
8. Melanoma immunotherapy.
Sanlorenzo M; Vujic I; Posch C; Dajee A; Yen A; Kim S; Ashworth M; Rosenblum MD; Algazi A; Osella-Abate S; Quaglino P; Daud A; Ortiz-Urda S
Cancer Biol Ther; 2014 Jun; 15(6):665-74. PubMed ID: 24651672
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.
Ascierto PA; Kalos M; Schaer DA; Callahan MK; Wolchok JD
Clin Cancer Res; 2013 Mar; 19(5):1009-20. PubMed ID: 23460532
[TBL] [Abstract][Full Text] [Related]
11. Metastatic melanoma and immunotherapy.
Herzberg B; Fisher DE
Clin Immunol; 2016 Nov; 172():105-110. PubMed ID: 27430520
[TBL] [Abstract][Full Text] [Related]
12. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.
Sapoznik S; Hammer O; Ortenberg R; Besser MJ; Ben-Moshe T; Schachter J; Markel G
Clin Dev Immunol; 2012; 2012():818214. PubMed ID: 22778766
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and the concept of a clinical cure.
Eggermont AM; Kroemer G; Zitvogel L
Eur J Cancer; 2013 Sep; 49(14):2965-7. PubMed ID: 23890942
[TBL] [Abstract][Full Text] [Related]
14. Combination Immunotherapy Development in Melanoma.
Eggermont AMM; Crittenden M; Wargo J
Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
[TBL] [Abstract][Full Text] [Related]
15. Tumor immunotherapy in melanoma: on the dawn of a new era?
Wilcox R; Markovic SN
Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
[TBL] [Abstract][Full Text] [Related]
16. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
[No Abstract] [Full Text] [Related]
17. The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma.
Soergel SA; MacEwen EG; Vail DM; Potter DM; Sondel PM; Helfand SC
J Immunother; 1999 Sep; 22(5):443-53. PubMed ID: 10546161
[TBL] [Abstract][Full Text] [Related]
18. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
Esper P
Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
[TBL] [Abstract][Full Text] [Related]
19. Advances in immunotherapy for melanoma management.
Dany M; Nganga R; Chidiac A; Hanna E; Matar S; Elston D
Hum Vaccin Immunother; 2016 Oct; 12(10):2501-2511. PubMed ID: 27454404
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
